Percutaneous transluminal septal myocardial ablation in hypertrophic cardiomyopathy

Percutaneous transluminal septal myocardial ablation (PTSMA) is a new interventional technique to treat patients with hypertrophic cardiomyopathy. Small doses of ethanol 96% were injected into a targeted septal artery causing a chemical myocardial infarction. Three patients were evaluated, including...

Full description

Saved in:
Bibliographic Details
Published inNetherlands heart journal Vol. 9; no. 2; pp. 75 - 77
Main Authors van der Lee, C, Foley, D P, Vletter, W B, Ten Cate, F J, Kofflard, M J M
Format Journal Article
LanguageEnglish
Published Netherlands 01.05.2001
Subjects
Original
echocontrast
PTSMA
hypertropic cardiomyopathy
Online AccessGet full text

Cover

More Information
Summary:Percutaneous transluminal septal myocardial ablation (PTSMA) is a new interventional technique to treat patients with hypertrophic cardiomyopathy. Small doses of ethanol 96% were injected into a targeted septal artery causing a chemical myocardial infarction. Three patients were evaluated, including a follow-up of three months. There were no complications during the procedure LVOT gradient was reduced from 120±140 mmHg. At follow-up, all three patients showed improvement in validity. The method requires an echocardiographic contrast determination of the myocardium at risk for ethanol treatment, in addition to haemodynamic monitoring.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
tencate@card.azr.nl
ISSN:1568-5888
1876-6250